Payment overview · 2025
General Payments
$354.55
17 reported records · 9 companies
Healthcare provider profile · identity verified
Josh D. Gast, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · POPLAR BLUFF, MO · NPI 1437404761
Verified facts
What the public records show
CMS Open Payments records show Josh D. Gast, D.O. received $354.55 in general payments during 2025 across 17 reported records.
Alkermes, Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $92.21 | 26.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.45 | 19.6% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $57.65 | 16.3% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $41.68 | 11.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.89 | 6.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.72 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.88 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.18 | 4.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.89 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $354.55 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $70.33 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $57.65 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 169 |
| Losartan Potassium | Losartan Potassium | 374 | 96 |
| Gabapentin | Gabapentin | 346 | 83 |
| Lisinopril | Lisinopril | 345 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 77 |
| Carvedilol | Carvedilol | 215 | 57 |
| Nifedipine Er | Nifedipine | 203 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 63 |
| Celecoxib | Celecoxib | 199 | 60 |
| Omeprazole | Omeprazole | 182 | 48 |
| Furosemide | Furosemide | 156 | 49 |
| Montelukast Sodium | Montelukast Sodium | 148 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 47 |
| Glipizide | Glipizide | 124 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 29 |
| Metformin Hcl | Metformin Hcl | 123 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 31 |
| Potassium Chloride | Potassium Chloride | 107 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 23 |
| Metformin Hcl Er | Metformin Hcl | 89 | 25 |
| Januvia | Sitagliptin Phosphate | 83 | 15 |
| Trazodone Hcl | Trazodone Hcl | 83 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 32 |
| Pregabalin | Pregabalin | 76 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 19 |
| Sertraline Hcl | Sertraline Hcl | 73 | 22 |
| Jardiance | Empagliflozin | 70 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 23 |
| Allopurinol | Allopurinol | 64 | 14 |
| Tramadol Hcl | Tramadol Hcl | 63 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 17 |
| Eliquis | Apixaban | 58 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 18 |
| Famotidine | Famotidine | 56 | 17 |
| Baclofen | Baclofen | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 13 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 50 | suppressed |
| Ozempic | Semaglutide | 48 | 12 |
| Simvastatin | Simvastatin | 47 | 15 |
| Buspirone Hcl | Buspirone Hcl | 46 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | 14 |
| Naproxen | Naproxen | 44 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | 18 |
| Nitroglycerin | Nitroglycerin | 36 | 12 |
| Estradiol | Estradiol | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 25 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Prednisone | Prednisone | 26 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 24 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $354.55 · 17 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, BRIXADI, Cologuard Collection Kit, FANAPT, GEMTESA, LYBALVI, MOUNJARO, REXULTI, SPRAVATO, VIVITROL, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error